- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01394276
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
30. april 2016 oppdatert av: Hoffmann-La Roche
Rheumatoid Arthritis Patients Treated With Tocilizumab in Real Clinical Practice: Effectiveness and Safety (TRUST Study)
This observational study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis.
Data will be collected from patients for the 12 months following the first infusion of RoActemra/Actemra.
Studieoversikt
Status
Fullført
Forhold
Studietype
Observasjonsmessig
Registrering (Faktiske)
322
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Abruzzo
-
Coppito, Abruzzo, Italia, 67100
-
Pescara, Abruzzo, Italia, 65100
-
-
Calabria
-
Reggio Calabria, Calabria, Italia, 89133
-
-
Campania
-
Avellino, Campania, Italia, 83100
-
Gragnano, Campania, Italia, 80054
-
Napoli, Campania, Italia, 80131
-
Napoli, Campania, Italia, 80138
-
Napoli, Campania, Italia, 80144
-
Salerno, Campania, Italia, 84131
-
Telese Terme, Campania, Italia, 82037
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italia, 40138
-
Ferrara, Emilia-Romagna, Italia, 44100
-
Modena, Emilia-Romagna, Italia, 41100
-
Piacenza, Emilia-Romagna, Italia, 29100
-
-
Friuli-Venezia Giulia
-
Trieste, Friuli-Venezia Giulia, Italia, 34142
-
-
Lazio
-
Albano Laziale, Lazio, Italia, 00041
-
Roma, Lazio, Italia, 00168
-
Roma, Lazio, Italia, 00152
-
Roma, Lazio, Italia, 00189
-
Roma, Lazio, Italia, 00128
-
Roma, Lazio, Italia, 00145
-
Viterbo, Lazio, Italia, 01100
-
-
Liguria
-
Arenzano, Liguria, Italia, 16011
-
-
Lombardia
-
Castel Goffredo, Lombardia, Italia, 46042
-
Gavardo, Lombardia, Italia, 25085
-
Legnano, Lombardia, Italia, 20025
-
Milano, Lombardia, Italia, 20157
-
Monza, Lombardia, Italia, 20052
-
Pavia, Lombardia, Italia, 27100
-
Rozzano, Lombardia, Italia, 20089
-
Saronno, Lombardia, Italia, 21047
-
Treviglio, Lombardia, Italia, 24047
-
Vimercate, Lombardia, Italia, 20059
-
-
Marche
-
Ancona, Marche, Italia, 60020
-
Jesi, Marche, Italia, 60035
-
-
Molise
-
Agnone, Molise, Italia, 86081
-
-
Piemonte
-
Cuneo, Piemonte, Italia, 12100
-
Novara, Piemonte, Italia, 28100
-
Torino, Piemonte, Italia, 10126
-
-
Puglia
-
Brindisi, Puglia, Italia, 72100
-
Casarano (LE), Puglia, Italia, 73042
-
Foggia, Puglia, Italia, 71100
-
Martina Franca, Puglia, Italia, 74015
-
San Cesario Di Lecce, Puglia, Italia, 73016
-
-
Sardegna
-
Sassari, Sardegna, Italia, 07100
-
-
Sicilia
-
Catania, Sicilia, Italia, 95124
-
Gazzi, Sicilia, Italia, 98125
-
Palermo, Sicilia, Italia, 90127
-
Palermo, Sicilia, Italia, 90146
-
-
Toscana
-
Firenze, Toscana, Italia, 50139
-
Massa, Toscana, Italia, 54100
-
Pisa, Toscana, Italia, 56100
-
Prato, Toscana, Italia, 59100
-
-
Umbria
-
Perugia, Umbria, Italia, 06122
-
-
Veneto
-
Verona, Veneto, Italia, 37126
-
Verona, Veneto, Italia, 37134
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra
Beskrivelse
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria
- Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center
Exclusion Criteria:
- Current serious infection
- Hypersensitivity to the active component or any of the excipients
- Pregnant women
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Tocilizumab
Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed.
Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants Achieving Low Disease Activity After 6 Months of Treatment
Tidsramme: Up to 12 months
|
Low disease activity is defined as a disease activity score based on 28 joint count (DAS28) score lesser or equal to (</=) 3.2.
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3. Erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) measurement, 4. Participant's judgement on his own overall health status expressed by a visual analogue scale (VAS).
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
Percentage of participants with low disease activity was reported.
|
Up to 12 months
|
Percentage of Participants Achieving Disease Remission After 6 Months of Treatment
Tidsramme: Up to 12 months
|
Disease remission is defined as a DAS28 score < 2.6.
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3. ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
Percentage of participants with disease remission was reported.
|
Up to 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Mean Score of Disease Activity Based on 28 Joint Count in Participants on Monotherapy With Tocilizumab
Tidsramme: Baseline (Month 0), Month 1, Month 2, Month 4, Month 6, and Month 12
|
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3.ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
|
Baseline (Month 0), Month 1, Month 2, Month 4, Month 6, and Month 12
|
Mean Score of Fatigue Based on Visual Analogue Scale in Participants on Monotherapy With Tocilizumab
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
VAS for fatigue is a 100 mm scale for participant's assessment of their current level of fatigue.
The '0 'mm corresponds to "no perception of fatigue," '100 mm' is the "maximum level of fatigue that may be perceived."
Mean score of VAS fatigue in participants were reported.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Mean Score of Health Assessment Questionnaire in Participants on Monotherapy With Tocilizumab
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The health assessment questionnaire (HAQ) is a participant-completed questionnaire specific for RA, recommended by the American college of Rheumatology for the evaluation of quality of life.
It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities.
There are 4 possible responses for each question: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do.
To calculate HAQ, the participant must have a component set score for at least 6 of 8 component set.
The HAQ is the sum of the scores, divided by the number of component set that have a score (in range 6-8) for a total possible score of minimum/maximum i.e., 0 (best) to 3 (worst).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Number of Participants With Concomitant Medications
Tidsramme: Up to 12 months
|
Number of participants treated with at least one concomitant medication i.e., corticosteroid (Prednisone, Methyl prednisolone) was reported.
|
Up to 12 months
|
Percentage of Participants Discontinuing Treatment With Tocilizumab
Tidsramme: Up to 12 months
|
The percentage of participants who prematurely discontinued treatment with TCZ during the study period was reported.
|
Up to 12 months
|
Number of Participants With Any Adverse Events and Serious Adverse Events
Tidsramme: Up to 12 months
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment.
An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.
A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
|
Up to 12 months
|
Percentage of Participants Still on Tocilizumab Treatment Till 12 Months After the 1st Infusion
Tidsramme: Up to 12 months
|
Percentage of participants who continued treatment till 12 months after the first infusion with TCZ was reported.
|
Up to 12 months
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Second Metacarpo-phalangeal Joint of Right Hand.
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of synovial hyperplasia (SH) and joint effusion (JE) of second metacarpo-phalangeal (MCP) joint of right hand was determined by ultrasound examination.
According to the method proposed by Naredo, synovial hyperplasia and joint effusion were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Third Metacarpo-phalangeal Joint of Right Hand.
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of third MCP joint of right hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of third MCP joint of right hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intraarticular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Second Metacarpo-phalangeal Joint of Left Hand
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of second MCP joint of left hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of second MCP joint of left hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra-articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Third Metacarpo-phalangeal Joint of Left Hand.
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of third MCP joint of left hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of third MCP joint of left hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra-articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Mean Disease Activity Score Based on 28 Joint Count Score in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The DAS28 index applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints) 3. ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
The mean DAS28 scores were evaluated after the first infusion of TCZ in two different sub populations: participants with inadequate response (IR) to DMARD (DMARD-IR: group A) or to DMARD and anti-TNF drugs (DMARD + anti-TNF-IR: group B).
Data allowing the evaluation of DAS28 was available for 81 participants in DMARD-IR group and 203 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Mean Score of Fatigue Based on Visual Analogue Scale in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
VAS for fatigue is a 100 mm scale for participant's assessment of their current level of fatigue: 0 mm corresponds to "no perception of fatigue"; 100 mm is the "maximum that may be perceived".
The mean VAS fatigue scores were evaluated after the first infusion of TCZ in two different sub populations, classified according to the previous pharmacological treatment: participants with inadequate response to DMARD (DMARD-IR: group A) or to DMARD and anti-TNF drugs (DMARD + anti-TNF-IR: group B).
Data allowing the evaluation of fatigue (VAS) was available for 45 participants in DMARD-IR group and 113 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Mean Score of Health Assessment Questionnaire in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Tidsramme: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The HAQ is a participant-completed questionnaire specific for RA, recommended by the American college of Rheumatology for the evaluation of quality of life.
It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities.
There are 4 possible responses for each question: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do.
To calculate HAQ, participant must have a component set score for at least 6 of 8 component set.
The HAQ is the sum of the scores, divided by the number of component set that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst).
Data allowing the evaluation of HAQ was available for 73 participants in DMARD-IR group and 157 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2011
Primær fullføring (Faktiske)
1. april 2013
Studiet fullført (Faktiske)
1. april 2013
Datoer for studieregistrering
Først innsendt
13. juli 2011
Først innsendt som oppfylte QC-kriteriene
13. juli 2011
Først lagt ut (Anslag)
14. juli 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
7. juni 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. april 2016
Sist bekreftet
1. april 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ML25728
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .